Stockscreener 앱 받기
0.916
16.97%
0.1329
시간 외 거래:
.88
-0.036
-3.93%
전일 마감가:
$0.7831
열려 있는:
$0.77
하루 거래량:
1.21M
Relative Volume:
10.86
시가총액:
$4.50M
수익:
$29.57M
순이익/손실:
$-34.68M
주가수익비율:
-0.00129
EPS:
-708.7214
순현금흐름:
$-7.58M
1주 성능:
-3.59%
1개월 성능:
-57.79%
6개월 성능:
-95.44%
1년 성능:
-98.61%
1일 변동 폭
$0.7407
$1.00
1주일 범위
$0.725
$1.00
52주 변동 폭
$0.725
$77.63
재규어 헬스 Stock (JAGX) Company Profile
명칭
Jaguar Health Inc
전화
415-371-8300
주소
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Compare JAGX vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
0.916 | 3.73M | 29.57M | -34.68M | -7.58M | -708.72 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
재규어 헬스 Stock (JAGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-07-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-07-11 | 개시 | Rodman & Renshaw | Buy |
재규어 헬스 주식(JAGX)의 최신 뉴스
Jaguar Health Delays Quarterly SEC Filing - TipRanks
Jaguar Health (JAGX) cites major subsequent events in delaying Q2 2026 10-Q - Stock Titan
Jaguar Health (JAGX) details 40.9M-share resale tied to $40M equity line - Stock Titan
Jaguar Health (JAGX) Secures $2 Million Holdback Payment from Fu - GuruFocus
Why is Jaguar Health stock gaining today? - Investing.com
Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1 - ACCESS Newswire
After 12 Months, Crofelemer Cut Support Up to 48% in One MVID Patient - Stock Titan
Why is Jaguar Health stock gaining today? By Investing.com - Investing.com Australia
Jaguar Health (JAGX) Consolidates at $1.0: Support and Resistance Define Trading RangeMcClellan Summation - dars.gov.et
Jaguar Health (JAGX) Highlights Market Potential of Neonorm Dog Amidst Challenging Valuation - GuruFocus
Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog - Yahoo! Finance Canada
Jaguar Health Inc (JAGX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Jaguar Health Inc (JAGX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Jaguar Health, Inc. SEC Filing (Jul 27, 2026) - Stock Titan
Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID) - ACCESS Newswire
TradingKey - TradingKey
Jaguar Health Inc. (JAGX) Q1 2026 Earnings: Significant Earnings Miss Amid Absent RevenueDiluted EPS Report - dars.gov.et
Jaguar Health (NASDAQ: JAGX) puts major dilution and incentive plan votes to investors - Stock Titan
Jaguar Health Inc (JAGX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Jaguar Health (JAGX) Secures Compassionate Use for Crofelemer in EU - GuruFocus
Jaguar Reports Up to 48% Lower Weekly Support in One MVID Patient - Stock Titan
Jaguar Health (JAGX) Registration filing Summary - Quartr
Jaguar Health Company Profile & Introduction - Moomoo
JAGUAR HEALTH INC (JAGX) Stock Chart - ChartMill
Form S-1 Jaguar Health Inc For: 16 July By Investing.com - Investing.com South Africa
Enterprise value to EBIT forward of Jaguar Health, Inc. – FWB:1JA1 - TradingView
Jaguar Health (NASDAQ: JAGX) plans 5.5M-share resale registration - Stock Titan
Jaguar Health (NASDAQ: JAGX) details 40.8M-share, $40M equity line - Stock Titan
Jaguar Health | S-1: General form for registration of securities under the Securities Act of 1933 - Moomoo
Jaguar Health Napo And Alivus Enter New Manufacturing And Supply Agreement For CrofelemerSEC Filing - TradingView
Jaguar Health Extends Crofelemer Supply With Alivus Through 2029, Adds Minimum Purchase Commitments - TradingView
Jaguar Health (NASDAQ: JAGX) signs new crofelemer manufacturing pact - Stock Titan
Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs - ACCESS Newswire
Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program - ACCESS Newswire
MSN Money - MSN
Jaguar Health (JAGX) Lytham Partners Fall 2025 Investor Conference Summary - Quartr
Jaguar Health (JAGX) Proxy filing Summary - Quartr
Jaguar Health (JAGX) Slips 5.3%: Support Level in Focus After Recent DeclineMax Pain Level - dars.gov.et
Price to book forward of Jaguar Health, Inc. – FWB:1JA1 - TradingView
Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health - ACCESS Newswire
Jaguar Health stock and its path in specialty pharma. Investors weigh volatile moves - ad-hoc-news.de
Jaguar Health (JAGX) Slides 7.6% as Selling Pressure Tests Key Support ZoneCalendar Spread Trade - dars.gov.et
JAGXJaguar Health Inc Latest SEC Filings - Finviz
Jaguar Health to Present at Lytham Partners Fall 2022 Investor Conference on September 28th and at Ladenburg Thalmann 2022 Healthcare Conference on September 29th - ACCESS Newswire
Jaguar Health, Inc. Files 8-K Report on July 1, 2026 – Key Company Information & SEC Disclosure Details - Minichart
Jaguar Health Inc. Q1 2026 Earnings: EPS Falls Far Below Estimates, Stock Edges Higher Despite No Revenue - dars.gov.et
Enterprise value to revenue forward of Jaguar Health, Inc. – NASDAQ:JAGX - TradingView
Jaguar Health Completes Conversion of Series O Preferred - TipRanks
Jaguar Health (JAGX) completes Series O preferred stock conversion to common shares - Stock Titan
Jaguar Health Inc. (JAGX) Holds Steady at $2.96 as Stock Consolidates Near Key LevelsTriple EMA - dars.gov.et
Jaguar Health (JAGX) Showcases Crofelemer Data at ESPGHAN Conference - GuruFocus
재규어 헬스 (JAGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):